Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1383&sort=principal_investigator
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=principal_investigator", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=principal_investigator", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1384&sort=principal_investigator", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1382&sort=principal_investigator" }, "data": [ { "type": "Grant", "id": "15290", "attributes": { "award_id": "1K01DA058152-01A1", "title": "Exploring the antecendents and consequences of cannabis use in the context of coping: An experimental study", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Drug Abuse (NIDA)" ], "program_reference_codes": [], "program_officials": [ { "id": 28174, "first_name": "JOHN RAPHAEL", "last_name": "Fedota", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-01", "end_date": "2029-07-31", "award_amount": 188039, "principal_investigator": { "id": 31880, "first_name": "Carillon Joy", "last_name": "Skrzynski", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1583, "ror": "", "name": "UNIVERSITY OF COLORADO", "address": "", "city": "", "state": "CO", "zip": "", "country": "United States", "approved": true }, "abstract": "As cannabis legalization increases, there have been concurrent increases in use. A common reason for use is the mitigation of anxiety and stress, which has been exacerbated with the COVID-19 pandemic. However, cannabis use for coping purposes is associated with greater quantity and frequency (Q/F) of cannabis use, increased risk for cannabis-related problems, and greater likelihood for cannabis dependence. In turn, greater Q/F of cannabis use and dependence can lead to safety risks, mental/physical health issues, and other problems like greater Q/F of alcohol use. Thus, developing a greater understanding of cannabis use for coping purposes is a critical research endeavor. There are several important avenues of research that can inform our understanding of this use pattern. The first is examining if quantity of cannabis is actually increased when used for coping purposes, which has not yet been experimentally tested, as well as exploring factors that may moderate this effect (e.g., social anxiety and inhibitory control). A second avenue is investigating whether cannabis use actually mitigates stress. A third avenue is exploring the biological role of the endocannabinoid system as a mechanism by which cannabis use may relate to acute stress reduction as well as the role of cannabinoid content in this process. Specifically, research shows that the endocannabinoid, arachidonoyl ethanolamide (AEA), is negatively associated with anxiety and stress such that it may mediate the relationship between cannabis use and stress reduction. Because the two main cannabis constituents, 9-delta tetrahydrocannabinol (THC) and cannabidiol (CBD), are associated with disparate effects on AEA, they may differentially influence how cannabis use relates to stress. In particular, CBD may actually decrease stress compared to THC via greater effects on AEA production. This study proposes to examine these research questions with four aims. The first will experimentally test a causal relationship between cannabis use for coping purposes and quantity of cannabis use (i.e., if more cannabis is used after stress induction compared to a control condition among individuals who endorse cannabis use for coping purposes). The second will test if the relationship between stress and cannabis use is stronger for individuals with social anxiety and/or poorer inhibitory control. The third will test if cannabis use after stress is related to decreases in subjective and objective stress. The fourth will ask whether decreases in stress are mediated via increased AEA, and if this indirect relationship is stronger with greater CBD to THC product ratios. Knowledge gained from this study will have significant public health impact including aiding in intervention and prevention efforts for cannabis misuse and contributing data on the harm reduction potential of CBD.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15291", "attributes": { "award_id": "1R21AI185968-01", "title": "Pre-Analytic Factors affecting Molecular tests for Congenital Syphilis", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 23138, "first_name": "Jonathan A.", "last_name": "Glock", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-20", "end_date": "2026-07-31", "award_amount": 246000, "principal_investigator": { "id": 31881, "first_name": "Emily H", "last_name": "Adhikari", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 31882, "first_name": "Jeffrey", "last_name": "SoRelle", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1215, "ror": "", "name": "UT SOUTHWESTERN MEDICAL CENTER", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "Syphilis, caused by Treponema pallidum spp pallidum (T. pallidum), cases are rising at an alarming rate with devastating consequences for pregnant individuals and neonates. Syphilis in pregnancy carries a 21% increased risk for stillbirth, 6% increased risk for preterm delivery, and 9% increased risk for neonatal death. Some neonates with congenital syphilis manifest symptoms of disseminated infection before 2 years of age (early congenital syphilis) which carries a mortality rate of up to 38%. However, most neonates (60-90%) are asymptomatic at birth, and may develop symptoms of congenital syphilis later in life with risks for permanent damage to nervous, bone, eye, and musculoskeletal systems. There is currently no molecular diagnostic test for congenital syphilis in routine clinical use. Instead, indirect diagnosis of possible or probable infection relies heavily on neonatal serologic titer relative to maternal titer and maternal treatment history. Due to risks associated with a missed diagnosis of congenital syphilis and the lack of accurate diagnostics, treatment decisions are frequently subjective. There is a critical need for accurate, sensitive, and direct detection of syphilis infection to better inform diagnosis and treatment for congenital syphilis. Polymerase chain reaction (PCR)-based molecular tests have become routine for the detection of numerous infectious diseases due to the sensitivity and specificity of the technique. Sensitivity of PCR differs according to gene target, specimen type, and sampling technique. Despite attempts to develop PCR targeting regions of conserved genes like PolA and Tp47, no FDA approved syphilis PCR test exists. There is a gap in our understanding of the optimal sampling strategy for PCR as an adjunct to current algorithms for diagnosis of congenital syphilis and risk stratification, particularly in asymptomatic neonates. Therefore, we hypothesize that molecular PCR performance can be optimized by determining the best diagnostic specimen(s) for congenital syphilis in the context of maternal stage, treatment history and neonatal clinical evaluation. We have assembled a team to optimally address this hypothesis. Dr. Emily Adhikari is a maternal-fetal medicine specialist and Medical Director of Perinatal Infectious Diseases at Parkland Hospital where she supervises diagnosis and treatment of syphilis in pregnancy. In collaboration with neonatologist Dr. Shamaila Gill, and pediatric infectious disease specialist Dr. Amanda Evans, comprehensive neonatal diagnostic evaluation and clinical staging will be performed. Dr. Jeff SoRelle is trained in molecular genetic pathology and the requirements to clinically validate a test. He has developed several molecular tests including COVID-19 variants, which led him to collaborative efforts of the impact of Delta and Omicron variant infections in pregnancy with Dr. Adhikari resulting in publications in JAMA and Am J Obstet Gynecol. We propose the following aims: AIM 1: Determine whether PCR detects T. pallidum DNA in neonates exposed to maternal syphilis. AIM 2: Determine the best sample type and source for T. pallidum PCR.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15292", "attributes": { "award_id": "1F31HD115324-01", "title": "Associations among maternal stress, infant epigenetics, and behavioral and cognitive development across the first few years of life", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 8605, "first_name": "JAMES", "last_name": "GRIFFIN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-01", "end_date": "2026-07-31", "award_amount": 42574, "principal_investigator": { "id": 31883, "first_name": "Jessica", "last_name": "Sperber", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2526, "ror": "", "name": "COLUMBIA UNIVERSITY TEACHERS COLLEGE", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "This F31 NRSA application will provide the applicant with the training necessary to achieve their goal of becoming an independently-funded researcher integrating perspectives from developmental psychology, neuroscience, and prevention science. This dissertation project seeks to incorporate epigenetic aging as a biomarker and potential mechanism to explain the association between maternal stress and behavioral and cognitive development over the first few years of life. The application proposes training in: 1) the integration of epigenetic aging into the larger study of maternal stress and child development; 2) the methodology for DNA methylation extraction and analysis; and 3) advanced longitudinal models. The sponsorship team consists of experts in the fields of Psychology, Neuroscience, and Education from both Teachers College, Columbia University and University of Texas-Austin. The resources afforded by these sponsors and institutions will facilitate the applicant’s goal of integrating multimodal and interdisciplinary methods to improve the trajectories of children experiencing early life stress. RESEARCH PROJECT: Maternal stress during pregnancy and early childhood is a robust predictor of deleterious outcomes for children’s cognitive and behavioral development. Epigenetic processes are a powerful mechanism to explain how adverse experiences biologically embed to predict later functioning. Accelerated aging reflects a biological age that exceeds one’s chronological age, and is tightly linked with both early life stress and negative physical and mental health outcomes in adults. However, little is understood about these associations during early childhood. The reported spike in maternal stress since the onset of the COVID- 19 pandemic highlights the urgency with which researchers must examine how stress biologically embeds to predict later functioning. The present study will leverage an existing birth cohort of socioeconomically diverse families from New York City to examine the longitudinal associations among maternal stress, accelerated aging, and cognition and behavioral regulation in early childhood, with the following Aims: 1) Examine the longitudinal, stress-related alterations in epigenetic age across early childhood; 2) Examine biomarkers and cognitive effects of the COVID-19 pandemic in mothers and children; and 3) Examine whether accelerated aging predicts cognition and behavioral regulation in childhood. Maternal stress will be assessed both prenatally and at various points throughout the first three of years of the child’s life. Both perceived and physiological measures of stress will be examined in these associations. Children will provide saliva samples at 1-month and 30-months of age to examine epigenetic age and complete well-validated assessments of cognition and behavioral regulation at 30- months. Findings will elucidate the relationships between maternal stress and accelerated aging during childhood and the functional relevance of accelerated aging to children’s behavior and cognition.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15293", "attributes": { "award_id": "1U01IP001257-01", "title": "IP24-045, A Prospective Observational Study of Respiratory Virus Epidemiology in the Greater Boston Area", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Immunization and Respiratory Diseases (NCIRD)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2024-08-01", "end_date": "2029-07-31", "award_amount": 4500000, "principal_investigator": { "id": 31884, "first_name": "Kathryn Elaine", "last_name": "Stephenson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 771, "ror": "https://ror.org/04drvxt59", "name": "Beth Israel Deaconess Medical Center", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "Despite the extensive epidemiologic research conducted during the COVID-19 pandemic, there remain gaps in our knowledge about the epidemiology and transmission of priority respiratory viruses. For example, current surveillance networks in the United States are primarily limited to people who present for medical care and tend to enroll readily accessible populations like health care workers. The result is that policy makers have had limited insight into the epidemiology of respiratory viruses at the community-level, outside of medical settings and in fully representative populations. There is thus a great need for studies that can obtain data on young adults, children and pregnant women, as well as from diverse populations and socially vulnerable neighborhoods. This data would include information on the incidence and clinical burden of respiratory illnesses, attitudes towards preventive interventions, effectiveness of vaccines and antivirals, and duration of immunity following vaccination. In addition, changing viral characteristics with emerging SARS-CoV-2 variants has made it challenging to remain up to date with transmission characteristics, such as duration of infectiousness, attack rates, and determinants of household transmission. There is arguably even less known about these characteristics for influenza and respiratory syncytial virus (RSV), which are also major causes of morbidity. Such data are essential to advise on both protective public health and clinical guidelines to reduce respiratory virus-associated morbidity and mortality. To fill these knowledge gaps, we propose to conduct a prospective, longitudinal observational study of respiratory virus epidemiology in the Greater Boston Area, serving as a Pandemic Preparedness Cohort for the CDC. There are four components to our project, including an observational study with weekly symptom screening and symptomatic swabbing, an in-depth serologic sub-study, a case-ascertained household transmission study, and a data hub/analytic support initiative to coordinate the collective CDC Pandemic Preparedness Cohorts across the country. The overarching goal of our project is to support the US Health and Human Service Strategic Plan in safeguarding and improving national and global health conditions and outcomes.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15294", "attributes": { "award_id": "1R01EB035594-01", "title": "Designing a deployable and adaptable plasmonic sensing platform for infectious disease surveillance", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [ { "id": 27406, "first_name": "SHAWN PATRICK", "last_name": "Mulvaney", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-01", "end_date": "2028-04-30", "award_amount": 326944, "principal_investigator": { "id": 31885, "first_name": "Pietro", "last_name": "Strobbia", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1446, "ror": "https://ror.org/01e3m7079", "name": "University of Cincinnati", "address": "", "city": "", "state": "OH", "zip": "", "country": "United States", "approved": true }, "abstract": "This proposal aims to address the critical need for cost-effective, sensitive, and accurate point-of-need (PON) testing for infectious diseases by developing an adaptable and deployable sensing platform. Currently available molecular diagnostic tests, such as polymerase chain reaction (PCR) and lateral flow assays (LFA), exhibit limitations in terms of either ease of deployment or accuracy and sensitivity. This tradeoff between accuracy and cost-effectiveness/distribution has hindered the containment of the current pandemic and could limit our surveillance capabilities of emerging diseases. To overcome these challenges, we propose to develop catalytic surface-enhanced Raman scattering (SERS) sensors based on functional DNA sequences, offering several advantages over existing diagnostic methods. The long-term goal of this project is to create a sensing platform capable of detecting multiple genetic biomarkers in liquid biopsies, enabling effective PON diagnostics. The proposed SERS sensors provide highly multiplexed assays, improving accuracy in pathogen and variant identification. Furthermore, these sensors offer quantifiable results that can be used for prognostic purposes, enabling viral load determination. These SERS sensors are easily deployable and exhibit superior sensitivity compared to LFA, resulting in more accurate PON diagnostic tests. In this project, we plan to leverage inverse design and machine learning techniques to study the key functional DNA features that influence sensor performance. The insights gained for optimal design rules will be used to develop an automated sensor design algorithm capable of producing designs with predictable figures- of-merit, given a target genetic code. Additionally, we aim to exploit the reagentless feature of the sensors by developing lyophilized sensing tablets containing all necessary components for the sensing process. These tablets enable on- demand testing by simply adding the sample, thereby providing a practical means to administer this one-pot SERS assay at the PON. To validate these advancements, a multiplexed assay will be developed to detect SARS-CoV-2 and validated on saliva samples containing various inactivated viruses from different SARS-CoV-2 variants. We will test the diagnostic accuracy in the identification of viral load and specific variants.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15295", "attributes": { "award_id": "1R01AI179760-01A1", "title": "How Distinct Age-Associated B Cell Subsets Can Protect the Aged from Influenza", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 26918, "first_name": "Michelle Marie", "last_name": "Arnold", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-19", "end_date": "2029-07-31", "award_amount": 586250, "principal_investigator": { "id": 31886, "first_name": "Susan L", "last_name": "Swain", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 790, "ror": "", "name": "UNIV OF MASSACHUSETTS MED SCH WORCESTER", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "ABSTRACT: How Distinct Age-Associated B Cell Subsets Can Protect the Aged from Influenza. With age, the generation of T follicular helpers from naive CD4 T cells, and of germinal center B cells from follicular B cells, both of which are essential for the generation of high affinity antibody (Ab), become highly compromised. Most current vaccines for influenza in the elderly are ineffective at inducing these critical responses. Thus, the elderly, though protected by Ab already in place for pathogens encountered earlier in life, are highly susceptible to new strains of virus (e.g. new yearly variants of influenza) and newly emerged pathogens (e.g. pandemic influenzas, COVID-19). In aged mice, we noted the generation of an unusual population of Ab-secreting B cells in response to live influenza infection. We found they are derived from stimulation of recently described \"age-associated B cells\" (ABC) rather than conventional naïve follicular B cells. In aged mice influenza-induced ABC (iABC) responses are generated independently of CD4 T cell help, but are strictly depend on stimulation by pathogen- associated \"danger\" signals. Notably, the ABC are the predominant naïve B cells that respond to influenza infection in aged mice. We find only the IgD ABC subset of naïve ABC, respond, and that IgD ABC include two subsets, T-bet+/CD11c+ and T-bet-/CD11c-. Here we will determine the potential of each of these to respond to infection and generate Ab-secreting cells (AbSC), B cell memory and long-lived Ab-secreting cells in the lung and nasal tissues as well as the spleen, lymph node and bone marrow and define what signals from the influenza infection are needed. We will determine the contribution of the T-bet and non-T-bet responses to protection from reinfection. We will compare the ability of live influenza virus, whole inactivated virus and mRNA-LNP vaccine to generate ABC-derived responses and induce protective immunity, and test if adding infection-associated signals improves this. These results will give us new insights into this novel age-associated immune pathway and should provide new indications of how vaccines can be improved to provide more robust protection to the elderly who currently are highly vulnerable.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15296", "attributes": { "award_id": "1R25AI175011-01A1", "title": "Integrated Training Program in Vaccinology (ITP-Vax)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 31247, "first_name": "MADELYN", "last_name": "Reyes", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-15", "end_date": "2029-07-31", "award_amount": 352643, "principal_investigator": { "id": 31887, "first_name": "Sharon Mei", "last_name": "Tennant", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 793, "ror": "", "name": "UNIVERSITY OF MARYLAND BALTIMORE", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "Vaccination has had a profound impact on human health and has eradicated or almost eradicated once feared diseases such as smallpox and polio and substantially decreased morbidity and mortality due to pneumococcus, measles and pertussis amongst many others. The utility and cost effectiveness of vaccination has been shown multiple times and most recently during the COVID-19 pandemic. SARS-CoV-2 has had a devastating effect on humankind causing significant morbidity and mortality as well as major disruptions to the economy, education, the supply chain and mental health. However, the extremely rapid development and deployment of multiple COVID-19 vaccines has allowed society to return to a semblance of normality. These vaccines were developed because of the large amount of money invested by governments to de-risk development and the many dedicated vaccinologists (laboratory personnel, clinical trialists, nurses, regulatory affairs specialists, statisticians etc. in academia, government and industry) who were committed to working on a common goal. Additionally, novel vaccine platforms had been in development for many years so the knowledge about how these platforms could be harnessed for COVID-19 was already present. In order to be ready for the next pandemic, we need to ensure that there are sufficient individuals entering and staying in the field of vaccinology so that they can develop new platforms, evaluate and dissect immune responses, perform clinical trials and have a broad understanding of the entire vaccine development process. The overarching goal of the Integrated Training Program in Vaccinology (ITP-Vax) is to encourage more trainees to join the field of vaccinology, particularly under-represented minorities (URM), and to enable our existing outstanding early-career vaccinologists to excel in mentorship and to become fully independent. To achieve this goal, we propose the following aims: Aim 1) To provide training in mentorship to early-career investigators and assist them on their path to independence in vaccinology, and Aim 2) To provide comprehensive training in vaccinology to post-baccalaureate or Master’s level students who are intending to apply for a PhD or medical school in the next 1-2 years and who seek a career in vaccinology. We will also actively engage and recruit URM’s for ITP-Vax so that we can ultimately improve diversity in vaccinology.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15297", "attributes": { "award_id": "1R01HL168579-01A1", "title": "Analysis of immunologic mechanisms in patients with chronic lung disease after acute COVID infection", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 22653, "first_name": "EMMANUEL FRANCK", "last_name": "Mongodin", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-15", "end_date": "2028-05-31", "award_amount": 752410, "principal_investigator": { "id": 31888, "first_name": "Homer L", "last_name": "Twigg", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2527, "ror": "https://ror.org/03eftgw80", "name": "Indiana University Indianapolis", "address": "", "city": "", "state": "IN", "zip": "", "country": "United States", "approved": true }, "abstract": "As of February 8, 2023 more than 102.7 million cases of SARS-CoV-2 infection leading to COVID-19 disease have occurred in the United States. Besides the acute morbidity and mortality associated with hospitalization, many patients with COVID-19 develop prolonged complications in the lung characterized by long term respiratory symptoms and radiographic changes due to pulmonary fibrotic and inflammatory processes. Some reports suggest 60-70% of patients who had severe COVID-19 infection will have residual pulmonary disease with fibrosis and/or ground glass opacities on chest imaging consistent with persistent lung inflammation. What drives the chronic immune and inflammatory response is unclear, but persistent viral antigen stimulation well after acute infection has resolved has been described in many viral infections. Persistent immune stimulation can lead to chronic inflammation through multiple mechanisms, including induction of innate immunity, chronic B and T cell responses, and immunosenescence, a highly pro-inflammatory process due to repeated T cell stimulation. In preliminary data we have extensively characterized the alveolar milieu in patients presenting with post COVID- lung disease up to 2 years after being diagnosed with acute infection. We have identified three patterns based on bronchoalveolar lavage (BAL) characteristics: a benign BAL pattern associated with stable lung scaring, a neutrophilic BAL pattern associated with increased cytokine concentrations and pulmonary fibrotic changes, and a lymphocytic pattern associated with increased chemokine concentrations and ground glass opacities on chest imaging. Importantly, we describe persistence in BAL of SARS-CoV-2 RNA in 85% of subjects and spike protein in half the subjects we have studies do far. In this project we hypothesize that chronic lung disease after COVID-19 infection is due to persistent viral proteins in the lung and a poor pulmonary immune response to SARS-COV-2. To address this hypothesis we propose the following specific aims. (1) To obtain bronchoalveolar lavage and peripheral blood for mechanistic studies on a cohort of patients who have persistent lung disease after acute COVID infection, including repeat follow up bronchoscopies on a subset of patients. (2) To further characterize BAL cellular and inflammatory patterns in patients with post COVID lung disease and link them with clinical diagnoses. (3) To assess COVID specific pulmonary humoral and cellular immune responses in patients with post COVID lung disease to determine linkages between COVID specific immunity, failure to clear viral RNA and proteins, and subsequent pulmonary disease. We have the capacity to recruit patients with post COVID lung disease who have BAL available for study and perform detailed cellular, inflammatory mediator, and SARS-CoV-2 specific immune analysis to explore potential mechanisms for the different pulmonary phenotypes seen. We feel the approaches utilized in this study will provide valuable information on post COVID lung disease, suggest approaches to management and treatment, and may be even be applicable to future studies on lung diseases after other viral infections.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15298", "attributes": { "award_id": "1R13AI186224-01", "title": "30th Annual Midwest Microbial Pathogenesis Conference (MMPC)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 22573, "first_name": "Barbara L.", "last_name": "Mulach", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-01", "end_date": "2029-07-31", "award_amount": 7500, "principal_investigator": { "id": 31889, "first_name": "Ankur", "last_name": "Dalia", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 31890, "first_name": "Julia C.", "last_name": "van Kessel", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1661, "ror": "", "name": "TRUSTEES OF INDIANA UNIVERSITY", "address": "", "city": "", "state": "IN", "zip": "", "country": "United States", "approved": true }, "abstract": "The recent COVID-19 pandemic, alongside the rise and recurrence of infectious diseases, has underscored the vital role of microbial science in addressing global public health challenges. The Midwest Microbial Pathogenesis Conference (MMPC) stands as an influential annual scientific meeting dedicated to showcasing exceptional research in microbial pathogenesis. MMPC focuses on nurturing the professional growth of junior faculty, students, and postdoctoral scholars, with a specific focus on those historically underrepresented in biological sciences, all while fostering an environment of diversity, equity, and inclusion for the exchange of scientific ideas and collaborations. Since its establishment in 1994, MMPC has been hosted yearly at academic institutions throughout the Midwest region of the United States. The steadily increasing attendance of >400 participants encompasses undergraduate and graduate students, postdoctoral fellows, research staff, and faculty, who engage in extensive interactions. Through career development forums, the \"Meet the Speakers\" series, and informal gatherings during poster sessions, receptions, and meals, MMPC 2024 aims to facilitate extensive networking among scientists and institutions across the Midwest and beyond. The conference's regional accessibility, affordability, and substantial financial support for travel and registration make it possible to attract a diverse array of participants. This meeting has been consistently supported by the NIAID over the past 14 years, and here, we are requesting continued support for MMPC 2024-2028. The 30th annual MMPC will be hosted by Indiana University in Bloomington, Indiana from September 6th-8th, 2024. In alignment with MMPC's rich tradition, >85% of the invited speakers (excluding the keynote and opening session speakers) will be trainees or junior faculty. Of the 15 invited faculty speakers, >50% are women and include diversity in terms of personal backgrounds, geographic origins, and research topics within the field of microbial pathogenesis. Additional oral presentations will be selected from abstracts submitted by students and postdoctoral fellows. As part of our commitment to promoting diversity and excellence, we aim to use funding from this grant application waive registration and lodging fees for 20 scholars who are women and/or from underrepresented groups. Further, we will waive the registration fee for an additional meritorious 13 trainees. MMPC 2024 will feature a keynote address by Dr. Kim Orth from the University of Texas Southwestern Medical Center, an esteemed HHMI Investigator, a Burroughs Wellcome Fund Investigator, and a member of the National Academy of Sciences. Dr. Orth will present her groundbreaking research on how pathogenic bacteria invade host cells and cause disease. Support of this R13 grant application from the NIAID will facilitate the assembly of a diverse group of scientists from various microbiology subdisciplines, encouraging collaborative networks and advancing the careers of the next generation of scientists.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15299", "attributes": { "award_id": "1R44CA291521-01", "title": "A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-601) Administered to Patients with Relapsed Non-Hodgkin Lymphoma", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [ { "id": 22312, "first_name": "Patricia A", "last_name": "Weber", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-01", "end_date": "2027-07-31", "award_amount": 665000, "principal_investigator": { "id": 31891, "first_name": "Juan fernando", "last_name": "Vera", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2528, "ror": "", "name": "MARKER THERAPEUTICS, INC.", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "This application presents MT-601, a novel multi-tumor associated antigen (mTAA)-specific T cell product for the treatment of Non-Hodgkin’s Lymphoma (NHL). NHL is the most common hematologic malignancy with ~80,550 new cases and >20,000 deaths in the US expected in 2023. Adoptive T cell transfer, e.g., CAR T cells, have impressive potency in NHL yet are also associated with cytokine release syndrome (CRS) and neurotoxicity. Additionally, relapse rates are up to 60% post-CAR T therapy due to low antigen levels or loss of CD19 expression. To date there are no approved therapies for NHL patients who relapsed after CAR T cell therapy, resulting in a huge unmet medical need for alternate treatment options for NHL. MT-601 represents a novel T cell-based immunotherapy that simultaneously targets 6 tumor-associated antigens (TAA) (PRAME, NY-ESO1, survivin, MAGE-A4, SSX2, WT1) that are overexpressed in NHL but absent or with limited expression in healthy tissue, thereby minimizing tumor escape and enhancing anti-tumor response. Manufactured from autologous apheresis material, MT-601 recognizes target cells via native T cell receptors by interacting with tumor antigen-expressing target cells presenting antigen in the context of both class I and II HLA, leading to killing of tumor cells expressing any of these antigens and recruiting the patient’s immune system in the anti-tumor response. Although other cellular immunotherapies attempt to address CD19 CAR T cell failures by targeting 2-3 antigens, they are limited by 1) narrow epitope recognition, and 2) leaving the tumor susceptible to relapse. In addition to broad-spectrum antigen targeting, MT-601 is the only cellular therapy being explored in NHL patients who relapsed following CAR T therapy. Additional advantages of MT-601 include out-patient administration and no genetic engineering. Furthermore, Marker’s multiTAA-specific technology was proven clinically safe in >180 patients with various kinds of cancer. In a phase 1 trial of lymphoma patients using multiTAA-specific T cells targeting 5 TAAs, patients had durable responses for much longer than those typically associated with CAR T cells (6 years versus 28 months). Notably, Marker recently treated our first CAR T cell relapsed NHL patient, who shows a complete response at 12 weeks post-infusion. Based on this promising clinical data, Marker proposes a single-arm Phase 1 clinical study to advance MT-601 for patients with NHL that relapsed after third line CAR T treatment and do not have other approved therapy options. The objective of Specific Aim 1 is to manufacture MT-601 and execute the clinical protocol by treating NHL patients who have relapsed after CD19 CAR T cell therapy with MT-601. Specific Aim 2 will correlate biological characteristics in the product profile with clinical safety and efficacy outcomes. Successful completion of this grant will provide clinical proof of concept for MT-601 as a treatment for CAR relapsed NHL patients, and support future clinical trials leading to future BLA filing and commercial approval of MT-601.", "keywords": [], "approved": true } } ], "meta": { "pagination": { "page": 1383, "pages": 1424, "count": 14236 } } }